PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC

作者：Federica Pecci, Mark Jeng, Alessandro Di Federico, M. Peroni, Federico Monaca, Emanuele Claudio Mingo, Lodovica Zullo, Daniele Marinelli, Andrea Torchia, Francesca Colamartini, Silvia Teresa Riva, Minh Tri Le, Ayesha Aijaz, Maisam Makarem, Eleonora Gariazzo, Biagio Ricciuti, Valentina Santo, Mihaela Aldea, Edoardo Garbo, Francesco Paoloni, Igor Gomez-Randulfe, Andrea De Giglio, Irene Zannini, Sara Stumpo, Francesco Mantuano, Alessandro Leonetti, Michela Verzè, Roberta Minari, Francesco Facchinetti, Stefano Scalera, Marcello Maugeri‐Saccà, Amanda Pupo, Stacey Frumm, Xinan Wang, Sara Baglivo, Emanuele Mazzola, Mizuki Nishino, Igor Odintsov, Lynette M. Sholl, Julia Rotow, Jaclyn LoPiccolo, Abdul Rafeh Naqash, Antoine Desîlets, Benjamin Besse, David Planchard, Alessio Cortellini, Roberto Ferrara, Giulio Metro, Federico Cappuzzo, Raffaele Califano, Andrea Ardizzoni, Marcello Tiseo, Helena Yu, Pasi A. Jänne · 发表于：Journal of Thoracic Oncology · 年份：2026 · DOI：10.1016/j.jtho.2026.104018 · 研究领域：Lung Cancer Treatments and Mutations、Colorectal Cancer Treatments and Studies、Gastrointestinal Tumor Research and Treatment